Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone know the current number of shares issued and outstanding?
This is getting close. Profusa Prospectus posted to SEC website on 1/29/2024.
Hello everyone. I am having trouble finding a Brokerage that will trade AXIM shares. I have tried Vanguard, TD Ameritrade, First Trade, Robinhood, Fidelity and Schwab, but with no luck. Can anyone please recommend a platform (or platforms) that they are using? Any recommendations are greatly appreciated. Godspeed.
Thank you guys for all your great DD.
I will be on special assignment, working, in my opinion, for the preservation of the Constitution that makes (or will once again make) this country the gem of the planet.
With strength, our Nation will lead the way to bringing Freedom to the rest of the World.
But freedom has a cost, one which I have always been willing to pay, in order to someday drain the swamps of domestic, treasonous enemies.
When the Lion returns to feed, may James 2:13 dictate all policies with no exceptions.
I have sworn my allegiance to the Constitution, and more importantly, those who, like myself, have taken the same oath.
Godspeed, and I will be back once I have concluded this current journey.
I know it is very ugly, but at least give it another week or two before you call time of death.
The selling right now could be just end of year tax loss/clean up portfolio time.
If things don't turn around by the second to third week of January, then I'm guessing it is time to pull the plug and start licking wounds.
Godspeed and a Safe and Happy New Year to all.
I'm thinking to give it a little more time.
I don't think it has bottomed out yet.
Six more trading days to the end of the year.
2023 should see this (finally) turn around, very slow at first, but then with a vengeance toward the mid to end of the year, IMHO.
Tough for those hanging in there, but there really isn't anywhere else to go (treasuries?) at this point.
Godspeed.
Agreed, but I can't think of any other plausible reason for the decline.
I'm guessing "tax selling" before the end of the tax year, 12/31/2022.
I think upon merger and renaming to Profusa, there will be about 100 million shares.
Since the target is known by the market, and the stock is now trading at a 52 week high of $10.05 (average volume under 11,000 shares per day, often times trades in the single digits or not at all on any given day), then I am convinced the pps will be above $10 per share upon merger ? I mean, why would anyone pay $10 a share now if they didn't believe that this had room to go upward?
The Lumee, when it gets its FDA approval (figure June 2023?) will compete with...or replace...Dexcom's G6 and/or Abbott's Freestyle Libre 2, both of which are big, clumsy, and have to be moved every 2 weeks.
Even my fairly inactive brother-in-law complains that he is always knocking his off, especially at night.
Check out DXCM's 5 year chart, just for sh$ts and giggles.
I know, apples to oranges, but there might be some long term potential there.
Or is AXIM just a bottomless pit?
https://www.globenewswire.com/news-release/2022/11/07/2550170/0/en/Profusa-Inc-a-Digital-Health-Company-Pioneering-the-Next-Generation-of-Personalized-Medicine-to-Become-a-Publicly-Traded-Company-Via-Merger-with-NorthView-Acquisition-Corp.html
https://www.globenewswire.com/news-release/2022/11/07/2550170/0/en/Profusa-Inc-a-Digital-Health-Company-Pioneering-the-Next-Generation-of-Personalized-Medicine-to-Become-a-Publicly-Traded-Company-Via-Merger-with-NorthView-Acquisition-Corp.html
https://profusa.com/about-us/
Clinical Laboratory Improvement Amendment waivers would be a whole new ballgame.
Such a waiver would make it so much easier to get the Axim platform of rapid result DED tests into even the smallest of ophthalmology offices.
I'm guessing the Versea/Axim teams can get that waiver approval by about the middle of 2023 (6 months or so from now).
Ordinarily, such an FDA approval would give a stock a nice bump upwards, but with Axim, you never know.
By the time they get the CLIA Waiver, Versea/Axim should have all the bugs worked out with the DED Diagnostic platform and their sales pitch perfected.
Six months later, by the end of 2023, hopefully most who have stayed on this (one way) rollercoaster ride will be back in the black and starting to see the light at the end of the tunnel.
Perhaps by the end of 2024, with the return to the fundamental values of the Constitution firmly re-established and the Republican/Conservative GOP (Good Ole' Party) now renamed the Patriot WTP (We The People) Party (The Meek shall inherit the earth, in its most literal sense), Versea/Axim will have taken advantage of the renewed economic growth expansion and firmly established itself (themselves) as a MAJOR player in the DED diagnostic market.
Would be nice to see Axim hitting a billion dollar market cap and trading at $4 to $5 a share sometime in mid to late 2025.
Godspeed.
Profusa received the following grants:
03/07/18 - 02/28/21 - Department of the Interior - $6.8 million grant
03/14/19 - 01/13/20 - Department of Defense - $224,864 grant
06/27/16 - 06/26/18 - Department of the Army/Department of Defense - $7.5 million grant
04/19/16 - National Institutes of Health - $1.75 million grant
06/22/12 - 02/22/13 - Department of Defense - $99,817 grant
https://www.todaysmedicaldevelopments.com/article/nih-medical-device-biosensors-profusa-41916/
https://www.fiercebiotech.com/medical-devices/profusa-awarded-7-5-million-darpa-grant-to-work-implantable-biosensors
https://www.usaspending.gov/keyword_search/profusa
Merger Information: https://www.spacinsider.com/news/mhaddad/northview-to-combine-with-profusa-in-416m-deal
Shares outstanding are currently 186.442 million shares.
I'd say that is a fair amount for a company and absolutely no reason to discuss a reverse split at this time.
Unfortunately, the issuing of more shares in order to raise capital to cover operations is potentially a strong possibility, especially if the DED test kit roll out drags on.
CLIA waiver would be a huge boost to sales if Axim/Versea could pull that off. The sooner the better.
Still, I originally envisioned AXIM topping off at around 200 million shares, perhaps now at 250 million unless sales pick up dramatically over the next few months.
Again, even 250 million shares for a company is not a lot, but it certainly would be pushing the upper limits of acceptability.
I still believe Axim has the right products at the right time (DED is becoming a big thing nowadays), and that Axim/Versea is something worth keeping an eye on in 2023.
PROFUSA is a medical devices company creating tissue-integrated sensors for chronic disease management and healthy living.
PROF-USA Made in America!
What an absolutely amazing choice for acquisition/merger.
Lumee looks to someday make the drawing of blood as archaic as using leeches as a cure.
Imagine the day when the 1st thing the PA does is shine a light on your PLI ("Personal Lumee Implant") as part of your yearly health check up.
Tweaked properly, I don't doubt that "Lumee" could even be used to determine blood types.
This is the kind of work that truly makes America Great.
Godspeed
(May I just casually toss out there that "PFSA" is currently an untaken stock symbol that is still available for use.)
Alleviating the Aggravation of Dry Eyes
There are many options for treating dry eyes depending on what works best for you
EYE HEALTH
Jacquelyn Waters
Jacquelyn Waters
Nov 20 2022
One of the simplest and most profound changes you can make for your dry eyes is to drink more water. (Prostock-studio/Shutterstock
This article is part two of a two-part series. Part one ran last week and described the symptoms, causes, and biology of this affliction.
You’ve likely experienced the incredible discomfort of having something in your eye. Whether an eyelash or piece of sand or dirt, you doubtless stopped what you were doing and attempted to get it out. Imagine this feeling being present for hours, or worse, for days on end.
This feeling is an ongoing reality for people who suffer from dry eye disease (DED). Symptoms of DED range from mild irritation to severe pain. You may experience burning, excessive tearing, sensitivity to sunlight, eye redness, and eye fatigue. DED is a complex disorder with multiple factors that contribute to and intensify the disease.
Dry Eye Is Complex
DED is often entwined with meibomian gland dysfunction in a vicious cycle in which the conditions exacerbate one another. Meibomian glands are oil glands along your eyelid margin that secrete the oily layer of your tear film. This oily layer normally prevents your eye’s tear film from evaporating too quickly. When the meibomian glands don’t function properly, they don’t secrete enough of a film to keep the watery portion of your tear film from evaporating. This leads to increased evaporation of the tear film, which causes the eyes to become dry and irritated. The dryness makes your eyes susceptible to pathogens, such as bacteria and viruses, and triggers the immune system to spur a cascade of inflammation, which further exacerbates meibomian gland dysfunction.
If you have symptoms of DED, the first step is to see an ophthalmologist who’s able to begin teasing apart the factors causing and perpetuating your dry eye symptoms.
Each case of DED is unique. Determining the driving factors contributing to and aggravating the condition is vital for proper management of the disease. There isn’t a one-size-fits-all approach. A good ophthalmologist will take the time to figure out which factors are contributing most significantly and address those factors specifically in order to break the cycle. If your ophthalmologist suggests treatments that you’re uncomfortable with and doesn’t seem to have given you a thorough exam, it may be wise to seek a second opinion.
Methods for Determining the Cause of Your Dry Eyes
A comprehensive eye exam with a full history of your general and eye health is foundational.
To measure your tear production, your ophthalmologist may perform a Schirmer’s test or phenol red thread test.
For the Schirmer’s test, one free end of a calibrated strip of filter paper is placed within each lower eyelid. You will keep your eyes closed for five minutes. After the five minutes, the paper is removed and the degree of wetting is measured.
The phenol red thread test causes less irritation than the Schirmer’s test. It utilizes a thin cotton thread that has been saturated with phenol red, a pH indicator. One end of each thread hooks over the lower eyelid of each eye. The patient maintains their gaze with normal blinking for 15 seconds, then the thread is removed. The wet part of the thread where tear fluid soaked is red and is measured to indicate how dry the eyes are.
In addition to measuring tear production, your ophthalmologist may test tear quality. The tear ferning test is an effective method to assess tear quality and help diagnose dryness. The ophthalmologist takes a small sample of tear fluid and places it onto a sterile glass microscope slide. When it dries, it produces a characteristic crystalline pattern called a “tear fern” that can be used to determine the quality of the tear fluid.
Your ophthalmologist may also perform a tear break-up time (TBUT) test. With this test, fluorescein eye drops are inserted into the eye. The patient is instructed not to blink while the tear film is observed by the ophthalmologist. The amount of time from the last blink to the appearance of a dry spot in the tear film is the TBUT value.
There are other eye drops with special dyes that can be used to view the surface of your eye. They’re used to look for staining patterns that reveal dryness, decreased tear film, and damage to the cornea.
The concentration of solute particles in the tear fluid can also be measured. This is called a tear osmolarity test. When the concentration of solute particles is above a certain osmolarity, it’s evidence there isn’t enough fluid in the tears being produced.
Your ophthalmologist can also take a sample of your tears and send the sample to a lab. The lab can test for markers of DED and inflammation, such as decreased lactoferrin and elevated matrix metalloproteinase-9.
Treating Dry Eye Disease Outside of the Clinic
The main goal of DED treatment is to restore the eye surface to a place of homeostasis where inflammation is under control and the factors necessary for a healthy tear film are re-established.
Addressing Environmental Factors
Environmental factors such as smoke and windy or dry climates can cause dry eye symptoms. Use of a humidifier, as well as avoiding sitting in the direct path of airflow from an air conditioner or fan are smart strategies for protecting your eyes. In addition, moisture chamber glasses can be very effective in these environments to protect the eyes from losing substantial tear film due to rapid evaporation.
Staring at a computer or smartphone screen for hours each day can contribute to dry eye symptoms due to infrequent blinking and eye strain. It may seem like a small thing, but setting reminders to take a rest from staring at the screen can be very beneficial.
Adjusting Lifestyle and Diet
One of the simplest and most profound changes you can make for your dry eyes is to drink more water. Set timers to remind yourself to drink water to make sure you’re adequately hydrated throughout the day.
Smoking and drinking excessive alcohol can cause dry eye symptoms; quitting smoking and keeping alcohol use in moderation are two powerful ways to decrease dry eye symptoms.
In some cases, an underlying autoimmune disorder may be the cause of DED. For instance, autoimmune thyroid disorders, Sjogren’s syndrome, rheumatoid arthritis, and lupus can all cause decreased tear production.
Determining what exacerbates symptoms of your autoimmune disorder can be key to helping your dry eye symptoms. For instance, elderberry can increase the production of inflammatory cytokines such as IL-1 beta, TNF-alpha, IL-6, and IL-8. Elderberry is contraindicated for those with autoimmune disorders. Echinacea can worsen autoimmune symptoms and therefore may aggravate dry eye symptoms in individuals with autoimmune disorders associated with decreased tear production.
Controlling inflammation in the body is important for decreasing autoimmune symptomology. A diet rich in anti-inflammatory foods, such as omega-3 fatty acids, is helpful for lowering inflammation in the body and at the surface of the eye.
Research on the role of omega-3 fatty acid supplementation on dry eye symptoms has been highly variable, but a recent systematic review and meta-analysis demonstrated improved subjective symptoms in patients with DED who supplemented with omega-3 fatty acids.
A meta-analysis of clinical trials reveals evidence that omega-3 fatty acid supplementation “significantly improves dry eye symptoms and signs in patients with dry eye disease.”
A diet high in processed foods, unhealthy fats, and sugar contributes to inflammation in the body and may be linked to your dry eye symptoms. A cross-sectional survey of 103 subjects suggests that “lower inflammatory diets such as the Mediterranean diet may have a protective effect against dry eye.”
Sometimes a vitamin deficiency is the cause of DED.
Vitamin D deficiency causes symptoms associated with dry eyes. In one study, researchers found vitamin D supplementation to be effective in treating patients who were deficient in vitamin D and not responding to conventional DED treatments. Another study revealed vitamin D supplementation improved dry eye symptoms, ocular surface conditions, and tear quality in older individuals who had dry eye symptoms.
DED can also result from vitamin A deficiency. In a small study of 30 males with dry eye, vitamin A supplementation improved the patients’ quality of tears.
Some medications, such as some antidepressants, antihistamines, hormone replacement therapy, and blood pressure medicines, may cause dry eye symptoms. Decreasing the dose or finding an alternative may bring relief from dry eye symptoms.
Lubricating Drops
For some DED patients, symptoms are mild enough that lubricating drops are enough to maintain comfort throughout the day.
There are two categories of lubricating drops: eyedrops with preservatives and preservative-free eyedrops. It is very important to use preservative-free eyedrops. In vitro and in vivo studies reveal preservative-free eyedrops result in the least amount of ocular surface disruption both clinically and on a cellular level. In particular, eyedrops with the preservative benzalkonium chloride (BAK) should never be used when a patient has DED.
Some over-the-counter lubricating drops come in the form of a gel, which can temporarily blur vision, but may give longer-lasting relief. Overnight ointments are another option to keep the eyes hydrated while you sleep.
When meibomian gland dysfunction is present with DED, as it often is, lipid-containing lubricants may provide better relief than lubricants without lipids.
It’s best to avoid drops that reduce redness through vasoconstriction as they can have a negative effect, called rebound hyperemia, in which your eyes become even more red and irritated.
Compresses and Lid Hygiene
For those with blocked meibomian glands, doing warm compresses daily is recommended to soften the meibum—the oily fluid that becomes part of the tear film—and allow it to flow out of the glands. A washcloth with warm water (around 113 degrees F) can be placed over the eyes for 10 minutes. There are also many different heating masks available on the market.
It’s also important to keep the eyelids clean. There are numerous types of eyelid wipes and cleansers available. You want to stay as natural as possible to avoid harsh chemicals on your eyes.
Clinical and Pharmaceutical Treatments
If the above modifications (environmental, lifestyle alterations, dietary habits, supplementation, and decreasing dosage of offending medicines) and basic treatments (lubricating drops, compresses, and lid washing) don’t successfully ameliorate dry eye symptoms, clinical and pharmaceutical treatments may be required. There are numerous options, but it’s important that your ophthalmologist tailor the treatment regimen for your specific case of DED.
If blepharitis—inflammation of the eyelids—is a compounding factor in your DED, your ophthalmologist may determine that a topical antibiotic is warranted. If there is an infestation of Demodex mites, they may treat your eyelids with tea tree oil or topical ivermectin.
Punctal plugs are little devices that are inserted in the eye’s puncta, tiny ducts that drain tears from the eye into the nasal cavity. Blocking these puncta allows tears to remain in the eyes longer. Temporary punctal plugs last for a few days to several months. They are often made of a material that breaks down over time, such as collagen. Semi-permanent plugs are designed to last for years. They are often made of material that is non-degradable, such as silicone.
There are also several treatment devices for removing blockages and expressing the meibomian glands.
Devices
LipiFlow Thermal Pulsation System is an increasingly popular treatment designed to remove meibomian gland blockages. The device uses a sterile activator to send heat pulses to meibomian glands while gently massaging the eyelids, unblocking the glands so the oil can flow freely.
ILux is similar to LipiFlow. It is a handheld device that warms and applies gentle pressure on your eyelids to unblock the meibomian glands.
In a clinical trial comparing iLux and LipiFlow for meibomian gland dysfunction treatment, both devices significantly improved meibomian gland function and symptoms, with no statistically significant differences in outcomes between devices.
Intense pulsed light (IPL) therapy is another therapy for those with meibomian gland dysfunction. With this therapy, gentle pulses of light are sent to the skin next to the eyes to decrease inflammation. These pulses warm hardened meibum blocking meibomian glands. In a three-year retrospective study, improvement in dry eye tear breakup time was found in 87 percent of patients after a series of IPL therapy sessions.
In addition to these therapies for unblocking meibomian glands, there are many types of prescription eye drops.
Eye Drops
If your ophthalmologist thinks you have a bacterial infection contributing to your DED, he or she may prescribe antibiotic eye drops.
Topical secretagogues—substances that promote secretion—can be aqueous or mucin-based and may be utilized by your ophthalmologist to increase production of the aqueous or mucous layers of the tear film.
There are also anti-inflammatory drops that can be prescribed.
If symptoms of inflammation and potential or actual ocular damage reach a certain threshold, your ophthalmologist may prescribe a corticosteroid eye drop or gel drop, such as Lotemax to calm the inflammation and allow the eyes to heal.
Non-glucocorticoid immunomodulator eyedrops, such as those containing cyclosporin A, such as Restasis and Cequa, may be used. It’s important to note these eyedrops may take 3 to 6 months of use before a change is noticeable.
Other Treatments
If the above treatments don’t bring relief, your ophthalmologist or an endocrinologist may prescribe an oral secretagogue, called a cholinergic, such as pilocarpine and cevimeline. These drugs stimulate the lacrimal gland to release more lacrimal fluid into the eyes.
Autologous blood serum eye drops are eye drops made from your own blood. To make these drops, a sample of your blood is processed to remove certain components, such as red blood cells. The blood serum is combined with a salt solution and placed into sterile eye dropper bottles.
The British Journal of Ophthalmology states, “While pharmaceutical lubricants offer little to no nutrition, eye drops made from autologous serum have a tear-like biochemical character and supply nutritional components.” This journal further notes that In vitro studies demonstrate autologous serum drops aid in the survival, proliferation, and migration of epithelial cells at the ocular surface.
Varenicline solution (Tyrvaya), is a nasal spray that helps treat dry eyes. Twice-daily administration of varenicline solution nasal spray was found to result in statistically significant improvements in DED symptoms over a four-week period in two studies.
Surgical Treatments
Sometimes a surgical approach is necessary to bring relief and prevent further eye damage.
Amniotic membrane grafts, such as Prokera, can provide significant healing to corneal tissue that has been damaged. Amniotic membranes are part of the placenta and are donated by consenting mothers after cesarean section. These tissues are rich in stem cells and have natural anti-inflammatory and anti-scarring properties.
Surgeries that might be necessary to protect eyes at risk of severe damage from lack of moisture include salivary gland transplantation and parotid duct transposition.
Surgical punctal occlusion is a permanent way to block the tear ducts. With this surgery, heat or laser will scar the puncta so that tears can’t drain through the puncta, keeping tears in the eyes longer.
Finally, in severe cases, tarsorrhaphy may be needed to prevent the patient from going blind. This is a surgical procedure in which the eyelids are partially sewn together to protect the cornea from permanent damage due to dryness. This procedure is used as a last-ditch effort in patients who can’t adequately close their eyes or have a condition in which the cornea is exposed in a prolonged manner. Such instances may possibly occur with Bell’s Palsy, myasthenia gravis, traumatic brain injuries, Grave’s disease, tumors behind the eye, and Sjogren’s syndrome.
Conclusion
While researchers continue to work to find treatment options for patients with DED, it’s important to remember how our environment, lifestyle, and diet can influence the health of our eyes. Being purposeful about staying hydrated, stepping away from screens periodically, and eating natural foods with healthy fats and vitamins, can make a difference in not only our ocular health, but in the health of our whole body.
References
Alanazi, S. A., El-Hiti, G. A., Al-Baloud, A. A., Alfarhan, M. I., Al-Shahrani, A., Albakri, A. A., Alqahtani, S., & Masmali, A. M. (2019). Effects of short-term oral vitamin A supplementation on the ocular tear film in patients with dry eye. Clinical ophthalmology (Auckland, N.Z.), 13, 599–604. https://doi.org/10.2147/OPTH.S198349
Bae, S. H., Shin, Y. J., Kim, H. K., Hyon, J. Y., Wee, W. R., & Park, S. G. (2016). Vitamin D Supplementation for Patients with Dry Eye Syndrome Refractory to Conventional Treatment. Scientific reports, 6, 33083. https://doi.org/10.1038/srep33083
Barak, V., Halperin, T., & Kalickman, I. (2001). The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines. European cytokine network, 12(2), 290–296. https://pubmed.ncbi.nlm.nih.gov/11399518/
Downie, L. E., & Keller, P. R. (2015). A Pragmatic Approach to Dry Eye Diagnosis: Evidence into Practice. Optometry and vision science : official publication of the American Academy of Optometry, 92(12), 1189–1197. https://doi.org/10.1097/OPX.0000000000000721
Flanagan, J., Huang, B., Tavakoli, S., Markoulli, M., & Papas, E. B. (2020, June 10). Is Dry Eye related to diet? Investigative Ophthalmology & Visual Science. Retrieved October 29, 2022, from https://iovs.arvojournals.org/article.aspx?articleid=2766476
Frampton J. E. (2022). Varenicline Solution Nasal Spray: A Review in Dry Eye Disease. Drugs, 1–8. Advance online publication. https://doi.org/10.1007/s40265-022-01782-4
Fraunfelder, F. T., Sciubba, J. J., & Mathers, W. D. (2012). The role of medications in causing dry eye. Journal of ophthalmology, 2012, 285851. https://doi.org/10.1155/2012/285851
Geerling G., MacLennan S., Hartwig D. (2004). Autologous serum eye drops for ocular surface disorders. British Journal of Ophthalmology; 88:1467-1474. https://bjo.bmj.com/content/88/11/1467
Giannaccare, G., Pellegrini, M., Sebastiani, S., Bernabei, F., Roda, M., Taroni, L., Versura, P., & Campos, E. C. (2019). Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials. Cornea, 38(5), 565–573. https://doi.org/10.1097/ICO.0000000000001884
Gilbert C. (2013). The eye signs of vitamin A deficiency. Community eye health, 26(84), 66–67. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936686/
Lee, A. N., & Werth, V. P. (2004). Activation of autoimmunity following use of immunostimulatory herbal supplements. Archives of Dermatology, 140(6). https://doi.org/10.1001/archderm.140.6.723
O’Byrne, C., & O’Keeffe, M. (2022). Omega-3 fatty acids in the management of dry eye disease-An updated systematic review and meta-analysis. Acta ophthalmologica, 10.1111/aos.15255. Advance online publication. https://doi.org/10.1111/aos.15255
Simsek, C., Dogru, M., Kojima, T., & Tsubota, K. (2018). Current Management and Treatment of Dry Eye Disease. Turkish journal of ophthalmology, 48(6), 309–313. https://doi.org/10.4274/tjo.69320
Tauber, J., Owen, J., Bloomenstein, M., Hovanesian, J., & Bullimore, M. A. (2020). Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. Clinical ophthalmology (Auckland, N.Z.), 14, 405–418. https://doi.org/10.2147/OPTH.S234008
Toyos, R., McGill, W., & Briscoe, D. (2015). Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomedicine and laser surgery, 33(1), 41–46. https://doi.org/10.1089/pho.2014.3819
Walsh, K., & Jones, L. (2019). The use of preservatives in dry eye drops. Clinical ophthalmology (Auckland, N.Z.), 13, 1409–1425. https://doi.org/10.2147/OPTH.S211611
Yang, C. H., Albietz, J., Harkin, D. G., Kimlin, M. G., & Schmid, K. L. (2018). Impact of oral vitamin D supplementation on the ocular surface in people with dry eye and/or low serum vitamin D. Contact lens & anterior eye : the journal of the British Contact Lens Association, 41(1), 69–76. https://doi.org/10.1016/j.clae.2017.09.007
Jacquelyn Waters
Jacquelyn Waters
Jacquelyn Waters writes about health, science, and medicine. She has particular interest in all things neuroscience—from molecular neuroscience to psychology. She has 8 years of experience teaching college biology and received her Master’s degree in biomedical sciences with a specialization in neuroscience from Vanderbilt University.
Is ANYTHING ever QUCIK and PAINLESS?
Well, I for one was disappointed to see that the 1st 6 months of sales was estimated to be a measly $150,000. Since I am estimating about $200,000 is needed per month to break even, it looks like there will be $ issues well into the new year.
I guess it is going to take some time for the new platform to take off. Hopefully AXIM gets a nice following of Drs who can give good, practical application reviews.
I'm sure a CLIA Waiver will be a huge plus.
Godspeed.
CE Mark: The EU consists of 28 countries with 750 million people.
Profusa has a CE Mark for Lumee in the EU, but for detecting Oxygen levels:
https://profusa.com/profusa-receives-cemark/
Certainly, if applying for Lumee 510K for glucose levels (and most likely oxygen levels as well) in the US, then Profusa will undoubtedly do the same in the EU.
In September, 2013, Dexcom was trading at just above $10 per share.
By 2022, it had a 52 week high of $164.86. It is trading was trading at $112.61 today (11/17/22) with 386 million shares outstanding, Market Cap = almost $44 billion.
After the merger, I am roughly estimating that the new company will have about 75 to 100 million shares.
I have no doubt that Axim has "built the better (if not best) mouse trap" for running these tests, and when the market realizes this, AXIM is going to infinity and beyond.
There are so many places that these tests can be inserted in order to cut down on time, complexity, and cost when it comes to diagnosis.
Add to that that the platform is easily expandible once the initial reader is purchased (as for instance, MMP-9).
I am willing to bet that everyone who has been holding AXIM to date wishes they had more powder available at these ridiculously low prices...
I think you are saying the system will be in 50,000 offices, but it also looks like you are only doing one pair of eyes per day?
If you figure 1/2 hour per visit, then there would be 16 patients per day, so when Axim hits full market saturation, you would be multiplying your $800,000 per day by 16.
Based on income, deferred income, and long term deferred income, Axim got $150,000.
I'd like to guess Axim manufacturers a kit for $6-$8 each, sells each kit to Versea for $15 (the 6 month traunch was 10,000 kits), and Versea sells to the doctors office for a bit over $17, the cost of which is fully reimbursable by the insurance company. The doctor's charge to do the test is included in the doctor's visit cost - one that would normally have taken more of the doctors time and effort had he NOT been using the Axim test kit platform.
In other words, the doctor could now see many more patients in a single day, get results immediately, and still charge the same consultation fee but just have many more of them in the same amount of time.
I'm just guessing at a scenario, but once Versea gets a doctor "hooked" on the platform, simply selling tests at a profit of $2.50 per test kit to REPEAT customers isn't a bad profit.
Just guessing, but it does sound plausible.... .
Peter O'Rourke (born January 3, 1966): 56 years old, currently Chairman of the Board of NorthView Acquisition Corp. Since December 2018, Mr. O’Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector. From January 2017 to December 2018, Mr. O’Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs under Donald Trump. From May 2015 to July 2016, Mr. O’Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O’Rourke also served both U.S. Navy and Air Force. Mr. O’Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force’s Institute of Technology. He previously worked in various positions in government consulting, including as a congressional staffer for U.S. Representative Tom Latham, and he also served as the executive director of the Republican Party of Florida.
Peter joined Axim's Board of Director's on July 21, 2020.
In April, 2021, Peter formed the SPAC North View Acquisition Corp., which began selling shares in December of 2021. On November 7, 2022, NVAC announced its intent to merge with Profusa, a company pioneering a novel, innovative approach to accurately, efficiently, and easily measure various biochemistry markers in real time using the Lumee hydromicrofiber.
In the European Union, the Lumee Oxygen Platform is CE Marked (January 28, 2020). In the United States, the Lumee Oxygen Platform is an Investigational Device Limited by Federal Law to Investigational Use.
The goal of the merger is to turn Profusa into a publicly traded entity by the first quarter of 2023, and thereafter to seek FDA approval for Lumee in the United States.
Lumee is a biosensor micro fiber that can immediately measure oxygen levels, glucose levels, exposure to biochemicals, even early signs of influenza - almost any biomarker of interest found in intercellular fluid without the "old technology way" of pin pricking and drawing blood.
In 2016, DARPA and the U.S. Army Research Office (ARO) awarded Profusa a $7.5 million dollar grant to develop the company’s implantable biosensors for the simultaneous, continuous monitoring of multiple body sensors. Profusa has focused research and product development on providing real-time monitoring of a combat soldier’s health status to improve mission efficiency and overall performance, partnering with DARPA to create breakthrough technologies and capabilities for our national security.
Peter O'Rouke's close ties to the US government for years is a nice match for Profusa's Lumee Military applications and its ultimate movement into civilian applications.
Currently, devices such as Abbott's Freestyle Libre 2 and Dexcom's G6 are expensive and must be moved every two weeks (to prevent rejection by the body).
The next big milestone event is the 10-Q, due out in 2 days (11/15/22), or if delayed one week as has been customary, then 11/22/22.
I think a lot of the questions we have been asking should be addressed within that report (what convertible loans are still outstanding?, how much was the 6 month advance payment?, what is the status of CLIA wavers?, etc.).
This 10-Q should mark the beginning of a new era for AXIM, one in which it definitively moves out of just being an R&D company and into a revenue generating entity.
I'm not expecting a jaw dropping report, but I am anticipating that there should be some notable details for Axim shareholders to discuss.
Godspeed.
Profusa:
10-Q due out in 3 days. Will Axim delay it again by another week? Maybe there is good reason to delay, but what it says to currently disenchanted shareholders speaks volumes, and not in a good way.
I do have to give an "at-a-boy" to one of Axim's staff. Over a year ago, Peter O'Rouke (who is on the board at Axim) formed a SPAC, which just last week (11/7/2022) finally announced its target - Profusa, Inc.
It looks like a smart choice, and I can see a lot of similarity in the business plan between the Axim/Sapphire merger and the NVAC/Profusa merger. Profusa has developed a tiny hydrofiber implant (3mm by .5mm) that is injected under the skin and does not elicit an immune/rejection response. This fiber can be used for months if not years, and when hit with certain wavelengths of light, molecules in this fiber fluoresce. The light that is emitted can be read and accurately reports various characteristics of intercellular fluid - such as glucose concentrations, oxygen levels, biochemical exposure (military uses), presence of flu particles, etc. Profusa already has a CE Mark for this fiber ("Lumee") in the EU and will seek FDA approval here in the United States after the merger is complete.
I could go on and on with how similar things are in the comparison between AXIM/SAPPHIRE and NVAC/PROFUSA (global market, multiple uses for the same "reader", novel product that is superior to current testing methods in a plethora of ways, R&D company at the onset of its revenue phase, etc.) but the most important point: Peter O'Rouke is on the Board at Axim and able to impart his same business brilliance to Axim, the business plan to bring Axim's products and Profusa's products to market are practically identical, tested, and proven, and the management at Axim (as we have seen) are serious professionals and crisis-tested experts with the goal of making their company and their products an unprecedented success.
It is going to take more time, but emerging companies with novel products that are more efficient, economical, and less invasive and inconvenient, with outstanding shares of 250 million or less and the potential for a not-so-far-into-the-future multi-billion dollar market cap are a rare find.
Godspeed to the Axim shareholders who have come this far and are willing to stick it out a bit longer.
Profusa has developed an injectable hydrofiber that does not trigger an immune response and can monitor blood chemistry for months to years, giving real time data that can be transmitted to medical technicians worldwide for immediate intervention. The results can be self monitored, so the individual can determine what actions they have taken which result in certain readings (such as eating a dessert and its effect on blood sugar levels), and can then take the necessary steps to correct any deviations.
https://profusa.com/
Lumee CE Mark of Approval January 2020
Study initiated to determine if Lumee can detect early Flu infection - March 3, 2020
Looks like the acquisition target was selected:
https://finance.yahoo.com/news/profusa-inc-digital-health-company-210000399.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAANeN6yZgDtAoUaydfITlBOpJsr1FivrVYFEDbH0zvaD_BorKQECYT6zI5zrtkLEvnUAgwSrdOdG9x8c5V7UEO_F7YHSQlK18wLno46-aR8jvSfBQlt8o-BO2pq3qE3QoW5RkfHnGgbV8iYv5e5hBkf9Qiq2aFPfk9S3J_pr-jNZg
Oddly announced on November 7th, when everyone was more likely focused on the November 8th midterm elections.
One thing to be on the look out for is the 10-Q due out 11/15.
Might speak volumes if it comes out on time!
Conversion of any notes outstanding into shares would be a positive sign. It would suggest that AXIM has bottomed out and that the insiders believe the pps would be heading North from where it is now.
I guess there was no need for a PR regarding the recent conference.
The 1st one was noteworthy, as it marked the launch of AXIM'S products.
The 2nd is just more attempts at selling, which is unremarkable in that this is what Versea/Axim will be doing henceforth, on a regular basis.
Besides, the only thing PRs have accomplished is a small boost in pps for a short time, and effecting the pps is NOT the purpose of a PR.
The PR is simply designed to keep the shareholders apprised of events that have a major impact on the company.
The 1st tradeshow fit that criteria. The 2nd (3rd, 4th, etc.) do not.
The second conference/tradeshow has come and gone. Is there any reason to believe it was better or worse than the first?
Even if some of the same players were there, it was a second chance to see what Versea was offering.
I can understand why JH would not want to PR the event before hand, in order not to raise expectations (over promise) when there is always the possibility that this show could under perform.
If there is no PR discussing the results of the show by Tuesday of this coming week, then it can be assumed that things didn't go as well as planned.
That scenario as to how the tradeshow went (is still going until tomorrow) sounds highly plausible, once the routine is established (which I am certain Versea has established a routine having marketed so many other products on a global scale).
I just think that if I were John H., I would want to pop in now and then (especially if the tradeshow is practically in my own backyard).
Seems I might want to see how my partner is doing things, especially with such a huge commitment (5 year exclusive agreement).
I guess a PR next week after the conference, highlighting the results, would be sufficient...
Tuesday would have been the right day for it.
Now I'm thinking it will be AFTER the conference, with conference results, more like Tuesday of next week.
We will soon see...
Yup. The conference starts on Wednesday, so Monday and Tuesday are open for PRs. I'm guessing we will hear something on Tuesday, since Monday isn't a good day for PRs, and no reason to do 2 back to back PRs when I'm pretty sure you could squeeze all the news into one.
This sounds plausible.
For those who failed to get in on the last note conversion, AXIM's volume is certainly low enough that the price could be manipulated, and with little chance of being detected.
I'm willing to bet, that is what we have seen the last couple of weeks...dropping the price over a 10 day period in order to get the lowest balance for a conversion.
A bit shady in my opinion, but truth be told, if that is what happened and the remainder of the notes are being converted, it kind of sucks but is a positive sign moving forward,
In other words, if the insiders believe this is the last chance to get their shares converted at the lowest price possible, that is great news.
It kind of suggests that AXIM has bottomed out and is now on its way up.
If that is correct, then maybe THIS TIME we have rounded the corner and its all mostly sunny skies from here on out.
With 330 million people in the US, and 7.75 billion worldwide (over 20x the population of the US), Versea' is most definitely focusing on the global market.
Its been just over 1 month since the contract was signed, and just under 1 month since the 1st conference that launched Axim's products, with another equally important conference less than a week away.
Can you imagine the electricity buzzing around both of these companies (Axim & Versea')?
As a global company, Versea' is literally working 24 hours a day, promoting Axim's products and seeking approvals overseas while the rest of us are sleeping over here.
I'm guessing the next groundbreaking announcements will be in the overseas markets, such as approvals by the EU and Canada. The markets in China, South America, and the Middle East, etc., certainly can't be ignored either, as DED is a problem that effects people on all continents.
Certainly no one is sitting around on their hands or twiddling their thumbs at either of these companies at this most critical time of development and expansion.
I don't doubt that those at Axim who think outside the box are also discussing further product possibilities.
2023 should prove to be a major breakout year for this small biotechnology start up.
I think so much could be answered if we only knew the size of that initial 6 month traunch.
I always figured Axim to settle in around 200 million outstanding so anything less would be a plus in my estimation.
With the conference starting on the 26th, do you think we will see a PR just before?